Pipeline

The company’s focus is on chronic disorders with major unmet medical need.

See more

Portfolio: Development status

Indication
Discovery
Preclinical
IND enabling
Phase 1
Phase 2
Phase 3
Neurogenic Detrusor Overactivity
Product: EG110A

Our lead asset, vector construct EG110A, has been designed to express a botulinum toxin fragment in bladder sensory neurons, whilst preserving motor neuron and muscle cell function, for treatment of NDO. EG110A has shown Proof-of-Concept efficacy in animal models and an IND data package is being prepared for submission.

 

Neurogenic Detrusor Overactivity:

A heavy patient burden with significant economic cost

The company’s primary focus is to treat a common urinary bladder dysfunction caused by spinal cord injury (SCI) and other neurodegenerative diseases such as multiple sclerosis (MS). This is the neurological disease known as neurogenic detrusor overactivity (NDO), responsible for various degrees of incontinence, as well as urinary tract infections and renal (kidney) damage than can lead to death in 5-10% of SCI population. NDO affects almost all (85-90%) of patients with SCI1 , and half of those with MS2 , and impacts on an individual’s independence and dignity. Over time, most patients do not respond to the standard pharmacological approaches to treatment, such as oral antimuscarinics or botulinum toxin injections. All those treatments aim at inhibiting the bladder muscle itself and there is therefore the associated need to empty the bladder using catheterization which is a high-risk factor for urinary infections.

Hamid, R., Averbeck, M.A., Chiang, H. et al. Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. World J Urol 36, 1517–1527 (2018). https://doi.org/10.1007/s00345-018-2301-z
2  Phé V et al., nrurol.2016.53 doi:10.1038, Management of neurogenic bladder in patients with MS

Medical need

Even with current available therapies, NDO remains a high medical burden, starting with induced urinary tract infections, which is the primary cause of hospitalization after an SCI.

EG110A for NDO is thus a major market opportunity, in the range USD 0.6bn to USD 1.5bn, as 80-90% of patients with spinal cord injuries are treated for bladder management.

15% - 20%

of patients are admitted each year post SCI3

$12K - $14K

estimated standard of care costs per year without hospitalization costs4

$10K

Hospitalization median costs5

Crescenze, I. M., Lenherr, S. M., Myers, J. B., Elliott, S. P., Welk, B., O'Dell, D., & Stoffel, J. T. (2021). Self-Reported Urological Hospitalizations or Emergency Room Visits in a Contemporary Spinal Cord Injury Cohort. The Journal of urology, 205(2), 477–482. https://doi.org/10.1097/JU.0000000000001386
Carlson et al., doi:10.1016/j.clinthera.2013.02.020, Estimating the Cost-Effectiveness of OnabotulinumtoxinA for Neurogenic Detrusor Overactivity in the United States
Belinda J. Gabbe, Andrew Nunn - Injury, Int. J. Care Injured 47 (2016) 1847–1855

Our solution

Using the characteristics of our nrHSV-1, our vector selectively silences the afferent nerves responsible for the aberrant behaviour of the neurogenic bladder. Preserving the ability of the bladder to contract, we want to offer patient a long-lasting treatment that restores continence and preserves volitional voiding either naturally or stimulated.

Indication
Discovery
Preclinical
IND enabling
Phase 1
Phase 2
Phase 3
Undisclosed neuromuscular disease
Product: EG132A
Indication
Discovery
Preclinical
IND enabling
Phase 1
Phase 2
Phase 3
Undisclosed sensory disease
Indication
Discovery
Preclinical
IND enabling
Phase 1
Phase 2
Phase 3
Other indications undisclosed outside PNS
×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.